Very-Low-Dose Decitabine Is Effective in Treating Intermediate- or High-Risk Myelodysplastic Syndrome

In conclusion, very-low-dose decitabine showed relatively good efficacy, good tolerance, and low medical cost in the treatment of intermediate- or high-risk MDS. Elderly patients with more than 1 complication or pati ents with a higher proportion of blast cells may be the most suitable candidates for this regimen.Acta Haematol 2017;138:168-174
Source: Acta Haematologica - Category: Hematology Source Type: research